Curcumin Cognition Randomized Trial: What the Evidence Says

Quick Answer

Curcumin Cognition Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 randomized trial.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Cognitive impairment, encompassing deficits in memory, attention, executive function, and processing speed, represents one of the most pressing global public health challenges associated with population aging. [Victoria-Montesinos Desirée (2026); evidence level 1]
• Complementing these estimates, data from the Global Burden of Disease (GBD) 2021 study indicate that the prevalence of Alzheimer's disease (AD) and related dementias (ADRD) among adults aged ≥65 years increased by approximately 160% between 1991 and 2021, rising from 18.7 million to 49 million affected individuals globally. [Victoria-Montesinos Desirée (2026); evidence level 1]
• In parallel, epidemiological evidence has consistently linked specific dietary patterns, such as the Mediterranean and MIND diets, to a reduced risk of cognitive decline and AD. [Kumari Ankita (2026); evidence level 2]
• These changes progress to reduced brain volume and are responsible for the memory loss associated with AD. [Kumari Ankita (2026); evidence level 2]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. There is trial evidence in the current set, but population and intervention details still matter. For curcumin cognition randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Victoria-Montesinos Desirée (2026). Effects of Zingiberaceae-derived interventions on memory-related and other cognitive outcomes in adults: a systematic review and meta-analysis. DOI: 10.3389/fnut.2026.1834167. PMCID: PMC13198985. PMID: 42199754. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13198985/
• Kumari Ankita (2026). Dietary Bioactives in Alzheimer’s Disease: A Critical Appraisal of Clinical Trials and Future Nutritional Strategies. DOI: 10.3390/nu18060907. PMCID: PMC13029159. PMID: 41901082. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13029159/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.